

INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS AND SHAREHOLDERS OF ZYDUS NOVELTECH INC.,

We have audited the accompanying financial statements of **ZYDUS NOVELTECH INC.,,** ("the Company") which comprise the Balance Sheet as at 31st December, 2014 and the Statement of Profit and Loss for the year ended on that date and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles and the Accounting Standards generally accepted in the respective country i.e. United States of America [USA]. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our broad review. We conducted the review of these financial statements in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We have not conducted any detailed audit procedures of these financial statements. However, we have carried out broad review of the certified financial statements as submitted by the management in accordance with the preceding paragraph. We believe that our broad review of financials provides a reasonable basis for our opinion. We also believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis our audit opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in USA:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company as at 31st December, 2014;
and
- (b) in the case of the Statement of Profit and Loss, of the loss for the year ended on that date.

Report on Other Legal and Regulatory Requirements

Further to our comments in the annexure referred to above, we report that:

- (i) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (ii) The accounts and financial statements duly prepared and certified by the Management in accordance with the accounting standards generally accepted and prevalent in USA. The accounts have been submitted to us for our review and have been appropriately verified and reviewed by us in preparing and submitting our report thereon.
- (iii) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
- (iv) In our opinion and to the best of our information and according to the explanations given to us, the said financial statements including Balance Sheet and statement of Profit and Loss dealt with by this report comply with the accounting standards generally accepted in USA.

- (v) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- a. The Company does not have any pending litigations which would impact its financial position.
 - b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - c. Since the Company is incorporated outside India, this clause regarding reporting on amounts which were required to be transferred to the Investor Education and Protection Fund by the Company is not applicable.

For Mukesh M. Shah & Co.
Chartered Accountants
Firm Registration No. 106625W

Ahmedabad

Date: 14th May, 2015

Partner
[Chandresh S. Shah]
Membership No.: 042132

Zydus Noveltech Inc.					
Balance Sheet as at December 31, 2014					
Particulars	Note No.	USD-Thousands		INR-Thousands	
		As at December 31			
		2014	2013	2014	2013
EQUITY AND LIABILITIES:					
Shareholders' Funds:					
Share Capital	1	5,000	5,000	315,300	299,700
Reserves and Surplus	2	(3,552)	(3,229)	(223,989)	(193,548)
		1,448	1,771	91,311	106,152
Current Liabilities:					
Short Term Borrowings	3	14,000	8,000	882,840	479,520
Trade Payables	4	207	318	13,053	19,061
Other Current Liabilities	5	82	419	5,171	25,115
Short Term Provisions	6	150	150	9,459	8,991
		14,439	8,887	910,523	532,687
Total		15,887	10,658	1,001,834	638,839
ASSETS:					
Non-Current Assets:					
Fixed Assets:					
Tangible Assets	7	11	23	693	1,379
Capital work-in-progress		16	9	1,009	539
		27	32	1,702	1,918
Non-Current Investments	8	100	100	6,306	5,994
Long Term Loans and Advances	9	12,877	9,405	812,024	563,735
		13,004	9,537	820,032	571,647
Current Assets:					
Trade Receivables	10	847	33	53,412	1,978
Cash and Bank Balances	11	1,964	1,017	123,850	60,959
Short Term Loans and Advances	12	8	10	504	599
Other Current Assets	13	64	61	4,036	3,656
		2,883	1,121	181,802	67,192
Total		15,887	10,658	1,001,834	638,839
Significant Accounting Policies	II				
Notes to the Financial Statements	1 to 23				
Statement of Profit and Loss for the year ended December 31, 2014					
Particulars	Note No.	USD-Thousands		INR-Thousands	
		Year ended December 31			
		2014	2013	2014	2013
REVENUE:					
Revenue from Operations:					
Sale of Service		2,646	2,140	161,485	128,272
Other Income	14	1	2	61	120
Total Revenue		2,647	2,142	161,546	128,392
EXPENSES:					
Employee Benefits Expense	15	1,406	1,559	85,808	93,446
Finance Costs	16	1	2	61	120
Depreciation and Impairment expenses	7	12	18	732	1,079
Other Expenses	17	1,551	1,310	94,657	92,448
Total Expenses		2,970	2,889	181,258	187,093
Loss for the year		(323)	(747)	(19,712)	(58,701)
				USD	INR
Basic & Diluted Earning per Common Stock [EPS]	18	(323)	(747)	(19,712)	(58,701)
Significant Accounting Policies	II				
Notes to the Financial Statements	1 to 23				
As per our report of even date		For and on behalf of the Board			
For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W					
Chandresh S. Shah Partner Membership Number: 042132 Ahmedabad, Dated: May 14, 2015		Director			

Zydus Noveltech Inc.

I-Company overview:

Zydus Noveltech Inc. [the "Company"], a New Jersey, U.S.A, corporation formed on June 18, 2007 is a development stage pharmaceutical company, which planning to engage in the sales and distribution of non-oral dosage form generic and brand name drugs in North America, Western Europe and Japan. In addition, Zydus Noveltech also provides technical and other services in support of drug development and manufacturing operations, as well as, business development services.

II-Significant Accounting Policies:

1 Reporting Currency Translations:

The Local accounts are maintained in local and functional currency which is "United States Dollar[USD]". These accounts have been translated in Indian Rupees considering the operation of the Company as "Non-integral operations" for holding company. The translation of Financial Statements to Indian Rupee [INR] from "USD" is performed for assets and liabilities using the exchange rates prevailing on the Balance sheet dates and for revenues and expenses items using the average exchange rates for the respective periods. The gain or loss resulting from such translation is included in "Foreign Currency Translation Reserve" under Reserves and Surplus.

2 Basis of presentation:

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

3 Property and Equipment:

Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The cost of improvements that extend the lives of assets are capitalized. Repairs and maintenance are expensed as incurred. Leasehold improvements are amortized over the lesser of the term of the related lease or the estimated useful lives of the assets. Estimated useful lives used range from three to seven years.

4 Impairment of Long-lived Assets:

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In performing a review for impairment, the Company compares the carrying value of the assets with their estimated future undiscounted cash flows. If it is determined that an impairment has occurred, the loss would be recognized during that year. The impairment loss is calculated as the difference between the asset carrying values and the present value of estimated net cash flows or comparable market values, giving consideration to recent operating performance and pricing trends. As a result of its review, the Company does not believe that any material impairment currently exists related to its long-lived assets.

5 Investments:

Long term and strategic investments are stated at cost, less any diminution in the value other than temporary.

6 Income Taxes:

The Company accounts for income taxes pursuant to the asset and liability method which requires deferred tax assets and liabilities to be computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

7 New Accounting Pronouncements:

Management does not expect the issuance of any recent accounting pronouncements to have a material effect on the financial condition or result of operation of the Company.

8 Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

9 Retirement Plan:

The Company has a 401(K) retirement plan that covers all employees. Employees may contribute a portion of their pre-tax salary.

The Company makes a Safe Harbor contribution to the plan for all employees, and also Profit Sharing contribution for certain employees.

10 Revenue Recognition:

A Service income is recognised as per the terms of contracts with the customers when the related services are performed or the agreed milestones are achieved.

B Interest income is recognised on time proportionate method.

C Revenue in respect of other income is recognised when no significant uncertainty as to its determination or realisation exists.

11 Borrowing Costs:

A Borrowing costs that are directly attributable to the acquisition/ construction of a qualifying asset are capitalised as part of the cost of such assets, up to the date the assets are ready for their intended use.

B Other borrowing costs are recognised as an expense in the year in which they are incurred.

12 Provisions, Contingent Liabilities and Contingent Assets:

Provision is recognised when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Contingent assets are not recognised in the financial statements. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates.

Zydus Noveltch Inc.				
Notes to the Financial Statements				
	USD-Thousands		INR-Thousands	
	As at December 31			
	2014	2013	2014	2013
Note: 1-Share Capital:				
Authorised:				
1,500 [as at December 31, 2013: 1,500] Common Stock, no par value	5,000	5,000	315,300	299,700
	5,000	5,000	315,300	299,700
Issued, Subscribed and Paid-up:				
1,000 [As at December 31, 2013: 1,000] Common Stock, no par value	5,000	5,000	315,300	299,700
	5,000	5,000	315,300	299,700
A There is no change in the number of stocks as at the beginning and end of the year				
Number of stocks at the beginning and end of the year	1,000	1,000		
B The Company has only Common Stock. All common stock rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the stock holders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts.				
C Details of Stock Holders holding more than 5% of Common Stock:				
Zydus International Private Limited, a company incorporated in the Republic of Ireland which is a subsidiary company of Cadila Healthcare Limited, the ultimate Holding Company, a company incorporated in India.				
Number of Stock	850	850		
% to total stock holding	85.00%	85.00%		
Mr. Sharad Govil				
Number of Stock	150	150		
% to total stock holding	15.00%	15.00%		
Note: 2-Reserves and Surplus:				
Foreign Currency Translation Reserve: [*]				
Balance as per last Balance Sheet	-	-	-	-
[Less]: Exchange Rate differences on translation to INR	-	-	(10,729)	-
	-	-	(10,729)	-
Surplus in statement of Profit and Loss:				
Balance as per last Balance Sheet	(3,229)	(2,482)	(193,548)	(134,847)
Add: Loss for the year	(323)	(747)	(19,712)	(58,701)
Balance as at the end of year	(3,552)	(3,229)	(213,260)	(193,548)
Total	(3,552)	(3,229)	(223,989)	(193,548)
[*] Hitherto, the gain/ loss arising on the translation of the Financial Statements to INR was given effect into Statement of Profit and Loss. However, from the year under report, it is now included in "Foreign Currency Translation Reserve" [FCTR] under Reserves and Surplus. Consequent to this change, loss for the year [in INR conversion only] is lower by INR 10,729 Thousands, with a corresponding effect in "Reserves and Surplus".				
Note: 3-Short Term Borrowings:				
Loan from a Bank [Secured] [*]	14,000	8,000	882,840	479,520
Total	14,000	8,000	882,840	479,520
[*] Loan from Bank of America [BOA] and Citi Bank [Citi]: Secured by corporate guarantee of Cadila Healthcare Limited. The interest on loan is payable at the rate of Daily LIBOR plus 100 bps for BOA and 0.8605% for Citi.				
Note: 4-Trade Payables:				
Trade Payables	207	318	13,053	19,061
Total	207	318	13,053	19,061
Note: 5-Other Current Liabilities:				
Others:				
Provision for Expenses	82	82	5,171	4,915
Advances from Debtors	-	337	-	20,200
Total	82	419	5,171	25,115
Note: 6-Short Term Provisions:				
Provision for Employee Benefits	150	150	9,459	8,991
Total	150	150	9,459	8,991

Zydus Noveltch Inc.
Notes to the Financial Statements

Note: 7-Fixed Assets:

	USD-Thousands				INR -Thousands			
	Leasehold Land	Plant and Equipment	Furniture and Fixtures	Total	Leasehold Land	Plant and Equipment	Furniture and Fixtures	Total
A Tangible Assets:								
Gross Block:								
As at December 31, 2012	10	82	91	183	543	4,455	4,944	9942
Additions	-	4	-	4	-	240	-	240
Disposals	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	56	461	512	1029
As at December 31, 2013	10	86	91	187	599	5,155	5,455	11,209
Additions	-	-	-	-	-	-	-	-
Disposals	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	32	268	283	583
As at December 31, 2014	10	86	91	187	631	5,423	5,738	11,792
Depreciation and Impairment:								
As at December 31, 2012	10	66	70	146	543	3,586	3,803	7,932
Charge for the year	-	5	13	18	-	300	779	1,079
Disposals	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	56	371	394	821
As at December 31, 2013	10	71	83	164	599	4,256	4,975	9,830
Charge for the year	-	6	6	12	-	366	366	732
Disposals	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	32	234	271	537
As at December 31, 2014	10	77	89	176	631	4,856	5,612	11,099
Net Block:								
As at December 31, 2013	-	15	8	23	-	899	480	1,379
As at December 31, 2014	-	9	2	11	-	567	126	693

Note: Other adjustments include adjustments on account of exchange rate translation differences.

	USD-Thousands		INR-Thousands	
	As at December 31			
	2014	2013	2014	2013

Note: 8-Non-Current Investments:

Long Term Investments :				
Trade Investments:				
Investment in fully paid Common Stock of a subsidiary company [Unquoted]:				
Hercon Pharmaceuticals LLC [Sole member] [Refer Note - 22]	100	100	6,306	5,994
Total	100	100	6,306	5,994

Note: 9-Long Term Loans and Advances:

Rent Deposit	11	11	694	659
Unsecured Loans and Advances to a related party - Hercon Pharmaceuticals LLC, a subsidiary company [Interest bearing loan] [Refer Note - 22]	12,866	9,394	811,330	563,076
Total	12,877	9,405	812,024	563,735

Note: 10-Trade Receivables:

Others- Considered good [Unsecured]	847	33	53,412	1,978
Total	847	33	53,412	1,978

Note: 11-Cash and Bank Balances:

Balances with Banks [*]	1,964	1,017	123,850	60,959
Total	1,964	1,017	123,850	60,959
[*] include to the extent held as margin money deposits against guarantee	393	482	24,783	28,891

Note: 12-Short Term Loans and Advances:

[Unsecured, Considered Good]				
Advances recoverable in cash or in kind or for value to be received	8	10	504	599
Total	8	10	504	599

Note: 13-Other Current Assets:

Prepaid Expenses	64	61	4,036	3,656
Total	64	61	4,036	3,656

Zydus Noveltch Inc.				
Notes to the Financial Statements				
	USD-Thousands		INR-Thousands	
	Year ended December 31			
	2014	2013	2014	2013
Note: 14-Other Income:				
Interest Income [Gross]:				
From Others [Other than long term/ current investments]	1	2	61	120
Total	1	2	61	120
Note: 15-Employee Benefits Expense:				
Salaries and wages	1,265	1,264	77,203	75,764
Contribution to provident and other funds	38	18	2,319	1,079
Staff welfare expenses	103	277	6,286	16,603
Total	1,406	1,559	85,808	93,446
Note: 16-Finance Costs:				
Bank commission & charges	1	2	61	120
Total	1	2	61	120
Note: 17-Other Expenses:				
Rent	60	50	3,662	2,997
Insurance	14	14	854	839
Traveling Expenses	204	131	12,450	7,852
Exchange Rate difference due to translation [Refer Note2 (*)]	-	-	-	13,927
Legal and Professional Fees	1,225	1,032	74,762	61,858
Miscellaneous Expenses	48	83	2,929	4,975
Total	1,551	1,310	94,657	92,448
Note: 18-Calculation of Earnings per Common Stock [EPS]:				
The numerators and denominators used to calculate the basic and diluted EPS are:				
A Loss attributable to Shareholders	(323)	(747)	(19,712)	(58,701)
B Basic and weighted average number of Common Stock outstanding during the year	1,000	1,000	1,000	1,000
	USD		INR	
C Basic & Diluted EPS	(323)	(747)	(19,712)	(58,701)
Note: 19-Related Party Transactions:				
A Name of the Related Parties and Nature of the Related Party Relationship:				
a Holding Company:		Zydus International Private Limited		
b Ultimate Holding Company:		Cadila Healthcare Limited		
c Subsidiary Company:		Hercon Pharmaceuticals LLC [USA]		
d Fellow Subsidiaries:				
Dialforhealth India Limited		Zydus Pharmaceuticals (USA) Inc. [USA]		
Dialforhealth Unity Limited		Nesher Pharmaceuticals (USA) LLC [USA]		
Dialforhealth Greencross Limited		Zydus France, SAS [France]		
German Remedies Limited		Etna Biotech S.R.L. [Italy]		
Zydus Wellness Limited		Zydus Pharmaceuticals Mexico SA De CV [Mexico]		
Liva Pharmaceuticals Limited		Zydus Pharmaceuticals Mexico Services Company SA De CV [Mexico]		
Zydus Technologies Limited		Simayla Pharmaceuticals (Pty) Ltd [South Africa]		
Biochem Pharmaceutical Industries Limited		Script Management Services (Pty) Ltd [South Africa]		
Zydus BSV Pharma Private Limited		ZAHL B.V. [the Netherlands]		
M/s. Zydus Healthcare, a Partnership Firm		ZAHL Europe B.V. [the Netherlands]		
M/s. Zydus Wellness-Sikkim, a Partnership Firm		Bremer Pharma GmbH [Germany]		
Zydus Lanka (Private) Limited [Sri Lanka]		Zydus Nikkho Farmaceutica Ltda. [Brazil]		
Zydus Healthcare S.A. (Pty) Ltd [South Africa]		Zydus Netherlands B.V. [the Netherlands]		
Zydus Healthcare (USA) LLC [USA]		Zydus Healthcare Philippines Inc. [Philippines]		
Laboratorios Combix S.L. [Spain]		Zydus Worldwide DMCC [Dubai]		
Zydus Pharma Japan Co. Ltd. [Japan]		Zydus Discovery DMCC [Dubai]		
e Directors:				
Mr. Pankaj R. Patel	Mr. Sharvil P. Patel	Mr. Sharad Govil		

Zydus Noveltch Inc.
Notes to the Financial Statements

Note: 19-Related Party Transactions-Continued:

B Transactions with Related Parties:

The following transactions were carried out with the related parties in the ordinary course of business:

a Details relating to parties referred to in items 19 - A [c & d]

<u>Nature of Transactions</u>	<u>Value of the Transactions [USD-Thousands]</u>			
	<u>Subsidiary Company</u>		<u>Fellow subsidiary</u>	
	<u>Year ended December 31</u>			
	<u>2014</u>	<u>2013</u>	<u>2014</u>	<u>2013</u>
Purchase:				
Reimbursement of expenses paid:				
Hercon Pharmaceuticals LLC	14	4		
Sales:				
Services:				
Zydus Technologies Limited			2,646	2,140
Reimbursement of expenses received:				
Zydus Technologies Limited			1	18
Hercon Pharmaceuticals LLC	230	137		
Finance:				
Inter corporate loan given:				
Hercon Pharmaceuticals LLC	3,472	6,165		
Inter corporate loan accepted:				
Zydus Pharmaceuticals (USA) Inc.			3,500	1,000
Inter corporate loan repaid:				
Zydus Pharmaceuticals (USA) Inc.			3,500	1,070
			<u>As at December 31</u>	
	<u>2014</u>	<u>2013</u>	<u>2014</u>	<u>2013</u>
Outstanding:				
Payable:				
Zydus Technologies limited				336
Receivable:				
Hercon Pharmaceuticals LLC	12,922	9,426		
Zydus Technologies limited			791	

<u>Nature of Transactions</u>	<u>Value of the Transactions [INR-Thousands]</u>			
	<u>Subsidiary Company</u>		<u>Fellow subsidiary</u>	
	<u>Year ended December 31</u>			
	<u>2014</u>	<u>2013</u>	<u>2014</u>	<u>2013</u>
Purchase:				
Reimbursement of expenses paid:				
Hercon Pharmaceuticals LLC	854	240		
Sales:				
Services:				
Zydus Technologies Limited			161,485	128,272
Reimbursement of expenses received:				
Zydus Technologies Limited			61	1,079
Hercon Pharmaceuticals LLC	14,037	8,212		
Finance:				
Inter corporate loan given:				
Hercon Pharmaceuticals LLC	218,944	369,530		
Inter corporate loan accepted:				
Zydus Pharmaceuticals (USA) Inc.			220,710	59,940
Inter corporate loan repaid:				
Zydus Pharmaceuticals (USA) Inc.			220,710	64,136
			<u>As at December 31</u>	
	<u>2014</u>	<u>2013</u>	<u>2014</u>	<u>2013</u>
Outstanding:				
Payable:				
Zydus Technologies limited			-	20,140
Receivable:				
Hercon Pharmaceuticals LLC	814,861	564,994		
Zydus Technologies limited			49,880	-

Zydus Noveltch Inc.
Notes to the Financial Statements

Note: 19-Related Party Transactions-Continued:

b Details relating to persons referred to in item 19-A [e] above :

	USD-Thousands		INR-Thousands	
	As at December 31			
	2014	2013	2014	2013
Outstanding:				
Receivable:				
Mr. Sharad Govil	8	10	473	631

b There are no transactions with persons referred to in item 19-A [a & b] above.

Note: 20-Segment Information:

There is only one segment, namely "Pharmaceuticals".

Note: 21-Operating Lease:

The Company has entered into an Operating Lease for its office and equipments, lease expiring through 2016. The future minimum rental payments under the lease agreement for the year ended December 31, 2014 and 2013 are as under:

	USD-Thousands		INR-Thousands	
	Year ended December 31			
	2014	2013	2014	2013
Year				
2014	-	49	-	2,990
2015	14	14	854	854
2016	1	1	61	61
Total Commitments	15	64	915	3,905
Lease payments recognised in the Statement of Profit and Loss	65	57	3,967	3,479

Note: 22

The Company has investment in Hercon Pharmaceuticals LLC, a subsidiary company of the Company. The accumulated losses as at December 31, 2014 amounting to USD 7,432 [as at December 31, 2013: USD 4,550] Thousands has exceeded the net worth of the said Company. However considering long term strategic nature of investment, investments and long term loans and advances granted to the said entity are considered good and accordingly no provision for the same has been made.

Note: 23

Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure.

Signatures to Significant Accounting Policies and Notes 1 to 23 to the Financial Statements

As per our report of even date

For Mukesh M. Shah & Co.,
Chartered Accountants
Firm Registration Number: 106625W

For and on behalf of the Board

Chandresh S. Shah
Partner
Membership Number: 042132
Ahmedabad, Dated: May 14, 2015

Director